AbbVie

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade AbbVie 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About ABBV

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders such as Parkinson’s disease, metabolic disorders, including thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. 

CEO
Robert A. Michael
CEORobert A. Michael
Employees
57,000
Employees57,000
Headquarters
North Chicago, Illinois
HeadquartersNorth Chicago, Illinois
Founded
2011
Founded2011
Employees
57,000
Employees57,000

ABBV Key Statistics

Market cap
452.53B
Market cap452.53B
Price-Earnings ratio
70.33
Price-Earnings ratio70.33
Dividend yield
2.75%
Dividend yield2.75%
Average volume
5.63M
Average volume5.63M
High today
$255.30
High today$255.30
Low today
$249.87
Low today$249.87
Open price
$251.73
Open price$251.73
Volume
2.04M
Volume2.04M
52 Week high
$267.47
52 Week high$267.47
52 Week low
$190.75
52 Week low$190.75

Stock Snapshot

As of today, AbbVie(ABBV) shares are valued at $250.97. The company's market cap stands at 452.53B, with a P/E ratio of 70.33 and a dividend yield of 2.75%.

During the trading session on 2026-08-13, AbbVie(ABBV) shares reached a daily high of $255.30 and a low of $249.87. At a current price of $250.97, the stock is +0.4% higher than the low and still -1.7% under the high.

Trading volume for AbbVie(ABBV) stock has reached 2.04M, versus its average volume of 5.63M.

The stock's 52-week range extends from a low of $190.75 to a high of $267.47.

The stock's 52-week range extends from a low of $190.75 to a high of $267.47.

ABBV News

Simply Wall St 19h
Did AbbVie’s Strong Q2, Higher 2026 Guidance, and New Approvals Just Shift AbbVie’s Investment Narrative? - simplywall.st

...

Did AbbVie’s Strong Q2, Higher 2026 Guidance, and New Approvals Just Shift AbbVie’s Investment Narrative? - simplywall.st
24/7 Wall St. 22h
Johnson & Johnson vs AbbVie: Safe Dividend vs Higher Yield

want a stake in closing that gap. See the offering → (sponsor) Goldman Sachs projects AI demand will exceed compute center capacity for years to come. One Sky...

Johnson & Johnson vs AbbVie: Safe Dividend vs Higher Yield
TipRanks 1d
AbbVie’s BOTOX Jawline Trial Wraps Up: What the Masseter Study Means for ABBV Investors

Abbvie (ABBV) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more confident invest...

Analyst ratings

78%

of 32 ratings
Buy
78.1%
Hold
18.8%
Sell
3.1%

More ABBV News

TipRanks 1d
AbbVie’s Venetoclax Combo in High-Risk MDS: What a Fresh Trial Update Signals for Investors

Abbvie (ABBV) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more confident invest...

24/7 Wall St. 1d
The Energy and Pharma Giants Quietly Funding HDV's 3% Yield, and How Safe Each One Is

The Energy and Pharma Giants Quietly Funding HDV’s 3% Yield, and How Safe Each One Is By David Beren Published Aug 12, 12:12PM EDT Quick Read XOM and JNJ earn...

The Energy and Pharma Giants Quietly Funding HDV's 3% Yield, and How Safe Each One Is
Nasdaq 2d
AbbVie vs. CVS Health: Which Healthcare Stock Is a Better Buy in 2026?

Key Points AbbVie leverages a strong specialty drug portfolio to offset the loss of exclusivity for its former top-selling products. CVS Health continues to e...

AbbVie vs. CVS Health: Which Healthcare Stock Is a Better Buy in 2026?
Simply Wall St 2d
What Is AbbVie Poised To Gain From FDA Review Of New BOTOX Use?

AbbVie (NYSE:ABBV) said the FDA has accepted for review a supplemental Biologics License Application for BOTOX Cosmetic to treat masseter muscle prominence in t...

What Is AbbVie Poised To Gain From FDA Review Of New BOTOX Use?
TipRanks 2d
Apogee Shareholders Approve AbbVie Acquisition and Leadership Transition

Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and...

TipRanks 2d
AbbVie Targets Key Lung Cancer Market With New Phase 3 ABBV-1480 Trial

Abbvie (ABBV) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more confident invest...

Nasdaq 2d
AbbVie Piles on $8 Billion in Debt for Its Apogee Deal -- Should Dividend Investors Worry?

Key Points AbbVie has been willing to supplement its new drug pipeline through acquisitions. It plans to pay $10.6 billion to purchase clinical-stage biotech...

AbbVie Piles on $8 Billion in Debt for Its Apogee Deal -- Should Dividend Investors Worry?

People also own

Based on the portfolios of people who own ABBV. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.